Market Overview

Report: uniQure Could Put Itself Up For Sale

Report: uniQure Could Put Itself Up For Sale

uniQure NV (NASDAQ: QURE) shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

uniQure is a gene therapy company exploring options amid interest from other pharmaceutical companies looking to expand in gene therapy.

The stock traded around $76.80 per share at time of publication after closing Friday at $72.55. The stock's 52-week higher is $78.02 and its 52-week low is $21.89.

Related Links:

6 Gene Therapy M&A Targets On The Radar

Sorrento Therapeutics Could IPO Its Scilex Unit

Posted-In: News Rumors Media


Related Articles (QURE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Report: Apple Has Eye On Gold Statues With Movie Developments

Scoop: Shopify And ParcelPal To Integrate For Cannabis Delivery In Canada